Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight loss in obese and overweight patients
NCT04605861Phase 3Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Liraglutide Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of body weight loss at 32 weeks and Proportion of body weight loss ≥ 5 percent at 32 weeks. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04605861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605861.